Eli Lilly (LLY) received a positive recommendation from the European Medicines Agency, or EMA, for its oral GLP-1 drug Foundayo for weight management and treatment of type 2 diabetes in adults, the EMA said Friday.
The EMA said patients in weight-loss trials lost about 5% to 11% of their body weight over 72 weeks, compared with 2% to 2.5% with placebo.
The drug also reduced HbA1c levels by 1.2 to 1.9 percentage points in diabetes studies.
The European Commission will make the final decision on EU marketing authorization, the watchdog said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments